Home -> Services -> Glaucoma Center -> Durysta Bimatoprost Implant
Durysta is also known as bimatoprost implant. It is a drug for ocular hypertension and open-angle glaucoma, and it should be administered through an outpatient therapeutic procedure.
The drug is administered with a sterile applicator after inserting the tip into the anterior chamber of the eye. The bimatoprost implant is released, the needle is removed, and the patient needs to sit for one hour to recover.
Within the eye, the implant releases the drug steadily for a 90-day period. It is a prostaglandin analog that stimulates the outflow of aqueous humor and reduces the intraocular pressure.
The FDA approved the bimatoprost implant because it is really effective. Compared to topical timolol eyedrops, Durysta reduced intraocular pressure by 30%, and is only administered once every 3 months instead of twice daily.
But would you prefer applying eyedrops twice a day over a 90-day implant? According to past experiences with patients, 83% of them said they were likely or very likely to undergo the procedure once again because it is not burdensome and makes their lives easier.
Durysta is useful in cases of open-angle glaucoma and ocular hypertension. However, not everyone is an ideal candidate for Durysta. It actually has a few contraindications:
In other words, it should only be used in patients with an open angle, good topical response to bimatoprost, and no underlying issue or infection in the cornea.
Texas Eye and Cataract, was the first practice in North Texas to perform this procedure.
If you would like to find out if you are a candidate for Durysta in North Texas, schedule an appointment. Our specialists will evaluate your case and inform you whether or not you’re a suitable candidate to try this new therapeutic option.
At Texas Eye and Cataract, we know how important it is to see life with clear vision. We understand that being your best means seeing your best.
Copyright © 2023 Texas Eye and Cataract. All rights reserved.
Copyright © 2022 Texas Eye and Cataract. All rights reserved.